The key role of RAASi therapy in patients with HF

10' education - Sep. 26, 2023 - Shelley Zieroth, MD - Winnipeg, MB, Canada

Video navigation menu

RAASi therapy is part of GDMT for HF 00:18
Suboptimal RAASi therapy 02:69
Hyperkalemia can be a barrier to target dose of RAASi 04:23
Suboptimal doses of RAASi associated with mortality and MACE 05:47
Summary 08:18

Educational information

This lecture by Shelley Zieroth, MD was part of the EBAC-accredited symposium "Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy" held at the ESC Congress 2023, Amsterdam, The Netherlands.

Faculty

Shelley Zieroth, MD is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, and Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital, Winnipeg, CA. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

Find here the slides of the presentation Watch the other videos of this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.